Kisspeptin-10: HPG Axis Regulation and Reproductive Health

Kisspeptin-10 is the shortest active fragment of kisspeptin, a brain peptide that sits at the very top of the reproductive hormone cascade known as the HPG (hypothalamic–pituitary–gonadal) axis. In small human studies, a single dose reliably triggers a rise in LH and testosterone, and related forms of kisspeptin have been studied as a gentler ovulation trigger in IVF. It is not FDA-approved, and long-term therapeutic trials are lacking.

Kisspeptin is one of the more elegant discoveries in modern endocrinology. It deserves interest, and also careful framing, because the gap between "important in physiology" and "proven as a treatment" is still wide.

Where Kisspeptin Sits in the HPG Axis

For decades, the hormone GnRH was considered the starting point of reproduction. We now understand that kisspeptin acts one step further upstream:

1. Kisspeptin neurons in the hypothalamus release kisspeptin.
2. Kisspeptin binds KISS1R (also called GPR54) on GnRH neurons.
3. GnRH is released in pulses into the blood supply of the pituitary.
4. The pituitary releases LH and FSH. Kisspeptin stimulates LH strongly and FSH more modestly.
5. The gonads respond. In men, LH drives testosterone; in women, the cycle of estrogen, ovulation and progesterone follows.

The key human evidence for this role came in 2003, when researchers reported that mutations in the GPR54 receptor caused failure to go through puberty. Without kisspeptin signaling, the reproductive axis does not switch on.

Kisspeptin as an Energy and Stress Sensor

Reproduction is biologically expensive, and kisspeptin neurons appear to help the brain decide whether conditions are right for it. Low energy availability from under-eating, very heavy training or severe stress is associated with reduced kisspeptin signaling and suppressed reproductive hormones. This helps explain conditions like hypothalamic amenorrhea in women and functional low testosterone in men who are overtrained or under-fueled.

What Human Studies Show for Kisspeptin-10

The human kisspeptin-10 evidence is real but small:

• Testosterone in men. In healthy men, kisspeptin-10 produced dose-dependent rises in LH and testosterone within hours.
• Hypothalamic amenorrhea. In women with this condition, kisspeptin restored LH pulsatility. Importantly, continuous exposure led to desensitization, meaning the receptor stopped responding.
• IVF. A 2015 study in women at high risk of ovarian hyperstimulation syndrome (OHSS) found that kisspeptin-54, a longer form, could trigger egg maturation with a low rate of OHSS. That is a specialist fertility application, not a general-use protocol.
• Sexual and emotional processing. Brain-imaging studies in men found that kisspeptin enhanced activity in regions involved in sexual and emotional responses.

What we do not have are long-term, controlled trials of repeated kisspeptin-10 use for low testosterone, low libido or fertility. Its half-life is only a few minutes, and the desensitization seen with continuous exposure means the pattern of dosing matters a great deal. Any dosing would be individualized and discussed only after evaluation and labs.

Kisspeptin and Testosterone Therapy

Standard testosterone replacement works, and for men with true hypogonadism it can be appropriate. But it suppresses the body's own LH and FSH, which reduces sperm production. For men who want to preserve fertility, approaches that stimulate the axis rather than replace its output are often considered.

Kisspeptin is interesting in that context because it acts at the very top of the cascade. However, it only works if the pituitary and testes can respond, and it has far less clinical evidence than established options. In practice, I more often discuss tools with stronger data, such as hCG or enclomiphene. See enclomiphene vs. TRT and hCG for fertility and testosterone support.

A Note on Kisspeptin and Cancer

The KISS1 gene was first identified in 1996 in melanoma research as a metastasis-suppressor gene, and laboratory work has explored its role in several cancers. This is a fascinating line of research, but it does not mean kisspeptin injections treat or prevent cancer. Because kisspeptin raises sex hormones, it is avoided in people with hormone-sensitive cancers such as prostate, breast or endometrial cancer.

Libido: How Kisspeptin Compares With PT-141

Low libido has many causes: hormones, relationship factors, mood, medications, sleep and general health. Kisspeptin may influence sexual motivation through its brain effects, but evidence is early. By contrast, PT-141 (bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, with clinical trial data behind that specific indication.

Regulatory Status

Kisspeptin-10 is not FDA-approved. FDA placed it in 503A Category 2 in 2023, and the Pharmacy Compounding Advisory Committee voted against adding it to the bulks list in October 2024, so it remains ineligible for routine compounding. As of this writing, check current FDA guidance before assuming any change. Athletes should treat it as prohibited. More details are in the kisspeptin-10 peptide library entry.

How I Evaluate Reproductive Hormone Concerns

At Laeeq M.D., the workup for low testosterone, irregular cycles or fertility concerns typically includes:

• LH, FSH, total and free testosterone or estradiol and progesterone
• SHBG and prolactin
• Thyroid function, CBC and metabolic panel
• Vitamin D
• Semen analysis when fertility is a goal

Sources

• Seminara SB, et al. The GPR54 Gene as a Regulator of Puberty. New England Journal of Medicine, 2003. https://pubmed.ncbi.nlm.nih.gov/14573733/
• Abbara A, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. Journal of Clinical Endocrinology & Metabolism, 2015. https://academic.oup.com/jcem/article/100/9/3322/2836046

Book a Consultation

If you are dealing with low testosterone, cycle changes or fertility questions, the answer starts with an accurate diagnosis. Dr. Laeeq offers a 60-minute evaluation, virtually or in Reston, VA. You can book a consultation to review your hormones and options.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.